ERBB2 and adenocarcinoma: Currently, there are no regimens for the treatment of HER-2 amplification that exclude targeted agents.<h4>Case presentation</h4>A 42-year-old man was diagnosed with adenocarcinoma of GEJ (stage IV) with liver metastasis and lung metastasis.